Indications and usage guidelines for ixazomib in the treatment of multiple myeloma

Ixazomib(Ninlaro), an oral highly selective proteasome inhibitor developed by Takeda Pharmaceuticals, provides a new treatment strategy for patients with multiple myeloma (MM). The following will elaborate on the application of ixazomib in the treatment of multiple myeloma and the correct way to take it.

1. Applicable situations

Ixazomib is particularly suitable for patients with multiple myeloma who have already undergone at least one line of therapy. When combined with lenalidomide and dexamethasone, it can more effectively control this malignancy caused by abnormal plasma cell proliferation. By inhibiting proteasome activity, ixazomib blocks further growth and spread of tumor cells. This drug is a prescription drug, please be sure to consult your doctor before taking it.

2. Usage Guide

1. Dosage and frequency: Patients are recommended to take ixazomib at a dose of 4 mg on days 1, 8 and 15 of each 28-day treatment cycle.

2. Taking time: In order to ensure the best absorption of the medicine, patients should take the medicine at least1 hour before a meal or 2 hours after a meal, and the taking time should be as consistent as possible every day.

3. How to take the medicine: The patient should swallow the capsule whole and drink it with water. Capsules should not be crushed, chewed, or opened to ensure the stability and effectiveness of the medication.

4. Special reminder: Treatment with ixazomib should be carried out under the guidance of doctors with experience in the treatment of multiple myeloma, and the treatment effect should be continuously monitored. If vomiting occurs after taking the medication, the patient does not need to take a supplementary dose and can just wait for the next planned dose time. For patients requiring long-term treatment (more than 24 cycles), the decision to continue treatment should be based on an individual assessment of risks and benefits.

Overall, ixazomib provides a new, effective treatment option for patients with multiple myeloma. However, for patient safety and therapeutic efficacy, medications must be taken strictly in accordance with medical advice and guidance. In addition, ixazomib has been marketed in China and can be reimbursed by medical insurance, reducing the financial burden on patients. At the same time, there are also more affordable versions of generic drugs available in overseas markets.